1. Home
  2. RGLS vs OPOF Comparison

RGLS vs OPOF Comparison

Compare RGLS & OPOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGLS
  • OPOF
  • Stock Information
  • Founded
  • RGLS 2007
  • OPOF 1922
  • Country
  • RGLS United States
  • OPOF United States
  • Employees
  • RGLS N/A
  • OPOF N/A
  • Industry
  • RGLS Biotechnology: Pharmaceutical Preparations
  • OPOF Major Banks
  • Sector
  • RGLS Health Care
  • OPOF Finance
  • Exchange
  • RGLS Nasdaq
  • OPOF Nasdaq
  • Market Cap
  • RGLS 102.1M
  • OPOF 103.7M
  • IPO Year
  • RGLS 2012
  • OPOF N/A
  • Fundamental
  • Price
  • RGLS $1.42
  • OPOF $21.14
  • Analyst Decision
  • RGLS Strong Buy
  • OPOF
  • Analyst Count
  • RGLS 6
  • OPOF 0
  • Target Price
  • RGLS $10.33
  • OPOF N/A
  • AVG Volume (30 Days)
  • RGLS 493.3K
  • OPOF 20.2K
  • Earning Date
  • RGLS 11-07-2024
  • OPOF 10-24-2024
  • Dividend Yield
  • RGLS N/A
  • OPOF 2.70%
  • EPS Growth
  • RGLS N/A
  • OPOF N/A
  • EPS
  • RGLS N/A
  • OPOF 1.60
  • Revenue
  • RGLS N/A
  • OPOF $59,503,000.00
  • Revenue This Year
  • RGLS N/A
  • OPOF N/A
  • Revenue Next Year
  • RGLS N/A
  • OPOF N/A
  • P/E Ratio
  • RGLS N/A
  • OPOF $12.73
  • Revenue Growth
  • RGLS N/A
  • OPOF N/A
  • 52 Week Low
  • RGLS $1.08
  • OPOF $13.49
  • 52 Week High
  • RGLS $3.79
  • OPOF $21.89
  • Technical
  • Relative Strength Index (RSI)
  • RGLS 41.95
  • OPOF 63.59
  • Support Level
  • RGLS $1.36
  • OPOF $20.30
  • Resistance Level
  • RGLS $1.65
  • OPOF $21.89
  • Average True Range (ATR)
  • RGLS 0.10
  • OPOF 0.66
  • MACD
  • RGLS -0.01
  • OPOF -0.03
  • Stochastic Oscillator
  • RGLS 28.57
  • OPOF 51.10

About RGLS Regulus Therapeutics Inc.

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

About OPOF Old Point Financial Corporation

Old Point Financial Corp functions in the financial services domain in the United States. As the holding company of The Bank and Trust, it is a nationally chartered trust and wealth management service, provider. Its suite of services includes commercial banking solutions such as loan, deposit and cash management, which are rendered through a chain of branches throughout the country. It operates through segments such as Bank, Wealth and Company.

Share on Social Networks: